Sign up USA
Proactive Investors - Run By Investors For Investors

Q BioMed announces favourable amendment to debenture financing

The new maturity date has been extended to November 30, 2018
Q BioMed announces favourable amendment to debenture financing
Q BioMed’s CEO, Denis Corin said: “We are pleased that this deal has worked out well for them and us and we will continue to work with them to secure the best outcome for both them and the rest of our shareholders.”

Q BioMed Inc (OTCMKTS:QBIO) said its funding partner, Yorkville Advisors has agreed to extend the maturity date on its US$2mln balance of the convertible note by one year.

The new maturity date has been pushed to November 30, 2018.

READ: Q BioMed says cancer pain drug will be available later this month

On November 29, last year, the biotech acceleration company entered into a securities purchase deal with Yorkville Advisors to place convertible debentures with a one-year term for US$4mln, with a 5% interest.

Q BioMed’s CEO, Dens Corin said: “We are pleased that this deal has worked out well for them and us and we will continue to work with them to secure the best outcome for both them and the rest of our shareholders.”

View full QBIO profile View Profile

Q BioMed Inc Timeline

Related Articles

1504120610_biotechLatest.jpg
October 23 2017
The company is poised for a milestone-rich period over the next year or so
1511808112_surgeon.jpg
January 08 2018
The device can now be sold to aid in heart treatment throughout the European Union
Harley Street sign
December 07 2017
The injection will bankroll the continuing technical development of the firm’s first LIGHT system and its installation at the Harley Street Proton Therapy Centre

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use